Topics

Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.

08:00 EDT 16th March 2020 | BioPortfolio

Summary of "Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration."

FGFR-TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR-TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3-TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.

Affiliation

Journal Details

This article was published in the following journal.

Name: Hematology/oncology and stem cell therapy
ISSN: 1658-3876
Pages:

Links

DeepDyve research library

PubMed Articles [4973 Associated PubMed Articles listed on BioPortfolio]

CAR T-cell Therapy in Hematologic Malignancies: A Voyage in Progress.

The development of chimeric antigen receptor (CAR) T-cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19-t...

PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count.

Peripherally inserted central catheters (PICCs) for central venous access are frequently used in patients with hematological malignancies. Their use may be complicated by upper extremity deep venous t...

Expression of non-coding RNAs in hematological malignancies.

With the advent of novel high throughput techniques, an extensive number of non-coding RNAs have been recognized to be involved in the pathogenesis of different types of hematological malignancies. Th...

Antibiotic treatment ameliorates Ten-eleven Translocation 2 (TET2) loss-of-function associated hematological malignancies.

TET2 is among the most frequently mutated genes in hematological malignancies, as well as in healthy individuals with clonal hematopoiesis. Inflammatory stress is known to promote the expansion of Tet...

Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study.

The aim of this study was to evaluate seizure outcome in children with hematological malignancies and PRES and to identify prognostic factors that could help manage the syndrome.

Clinical Trials [2781 Associated Clinical Trials listed on BioPortfolio]

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematolo...

Tissue Microarray of Hematological Malignancies

The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hem...

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

MS Detection of Somatic Mutations in Hematological Malignancies

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limi...

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Medical and Biotech [MESH] Definitions

Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.

The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.

Ordered rearrangement of B-lymphocyte variable gene regions coding for the IMMUNOGLOBULIN CHAINS, thereby contributing to antibody diversity. It occurs during the differentiation of the IMMATURE B-LYMPHOCYTES.

Ordered rearrangement of B-lymphocyte variable gene regions of the IMMUNOGLOBULIN HEAVY CHAINS, thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the IMMATURE B-LYMPHOCYTES.

Ordered rearrangement of B-lymphocyte variable gene regions coding for the kappa or lambda IMMUNOGLOBULIN LIGHT CHAINS, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the IMMATURE B-LYMPHOCYTES.

Quick Search


DeepDyve research library

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Searches Linking to this Article